6996 Stock Overview
A biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Antengene Corporation Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.62 |
52 Week High | HK$2.25 |
52 Week Low | HK$0.50 |
Beta | 0.81 |
11 Month Change | -13.89% |
3 Month Change | -41.51% |
1 Year Change | -52.67% |
33 Year Change | -95.85% |
5 Year Change | n/a |
Change since IPO | -96.61% |
Recent News & Updates
Recent updates
Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)
Jan 09The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%
Sep 20Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates
Apr 03We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate
Feb 19Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Nov 05We Think Antengene (HKG:6996) Can Afford To Drive Business Growth
Jun 28We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely
Mar 08We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely
Nov 18Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Aug 17Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Apr 29What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?
Feb 22Shareholder Returns
6996 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | 10.7% | 5.4% | -1.7% |
1Y | -52.7% | 4.2% | -5.9% |
Return vs Industry: 6996 underperformed the Hong Kong Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: 6996 underperformed the Hong Kong Market which returned -5.9% over the past year.
Price Volatility
6996 volatility | |
---|---|
6996 Average Weekly Movement | 7.9% |
Pharmaceuticals Industry Average Movement | 5.0% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.7% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 6996's share price has been volatile over the past 3 months.
Volatility Over Time: 6996's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 201 | Jay Mei | www.antengene.com |
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, Hong Kong, Macau, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR kinase inhibitor for the treatment of cervical cancer and other advanced solid tumors.
Antengene Corporation Limited Fundamentals Summary
6996 fundamental statistics | |
---|---|
Market cap | HK$418.43m |
Earnings (TTM) | -HK$631.87m |
Revenue (TTM) | HK$73.17m |
5.7x
P/S Ratio-0.7x
P/E RatioIs 6996 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6996 income statement (TTM) | |
---|---|
Revenue | CN¥67.31m |
Cost of Revenue | CN¥12.29m |
Gross Profit | CN¥55.01m |
Other Expenses | CN¥636.20m |
Earnings | -CN¥581.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 23, 2024
Earnings per share (EPS) | -0.86 |
Gross Margin | 81.74% |
Net Profit Margin | -863.51% |
Debt/Equity Ratio | 15.7% |
How did 6996 perform over the long term?
See historical performance and comparison